This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers

Inclusion Criteria:

• Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
• Age: ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months；
• Histologically or cytologically diagnosed with advanced cancers
• Subjects with advanced malignancies who have failed standard therapy or lack effective treatment
• Major organs are functioning well；
• Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.

Exclusion Criteria:

• Current concomitant presence of other malignancies within 5 years prior to the first dose；
• Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy
• Significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose
• Long-term unhealed wounds or fractures
• Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose
• Swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy
• A history of psychotropic drug abuse and cannot be abstained from or have a mental disorder
• Subjects with any severe and/or uncontrolled disease